Literature DB >> 11470054

Amyopathic dermatomyositis.

N J Olsen1, J H Park, L E King.   

Abstract

Amyopathic dermatomyositis is a variant of dermatomyositis that is characterized by the typical skin rash but without the muscle abnormalities. It has been proposed that the amyopathic and myopathic forms of dermatomyositis exist on a continuum, a concept that is supported by family and genetic studies and the observation that a small proportion of amyopathic patients transform to a frankly myopathic state. The amyopathic state is defined by a lack of muscle weakness and through diagnostic tests, including serum muscle enzymes, electromyogram studies, and muscle biopsies, that are usually normal or show only minimal abnormalities. Despite the lack of weakness, many patients complain of debilitating fatigue. More sensitive measures of muscle function, such as P-31 magnetic resonance spectroscopy, suggest that muscle metabolism is abnormal in amyopathic patients. The amyopathic form is more commonly seen in adults than in children, although juvenile cases are reported. Some early series suggested no association with underlying malignancies, but recent reports indicate that malignancies occur. Determining whether a patient has amyopathic rather than myopathic disease may have prognostic implications.

Entities:  

Mesh:

Year:  2001        PMID: 11470054     DOI: 10.1007/s11926-001-0039-9

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  44 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Guidelines of care for dermatomyositis. American Academy of Dermatology.

Authors:  L A Drake; S M Dinehart; E R Farmer; R W Goltz; G F Graham; M K Hordinsky; C W Lewis; D M Pariser; J W Skouge; S B Webster; D C Whitaker; B Butler; B J Lowery; R D Sontheimer; J P Callen; C Camisa; T T Provost; D L Tuffanelli
Journal:  J Am Acad Dermatol       Date:  1996-05       Impact factor: 11.527

3.  Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study.

Authors:  B Sigurgeirsson; B Lindelöf; O Edhag; E Allander
Journal:  N Engl J Med       Date:  1992-02-06       Impact factor: 91.245

Review 4.  Amyopathic dermatomyositis associated with malignancy.

Authors:  D R Finger; C L Dunn; W R Gilliland; W D James
Journal:  Int J Dermatol       Date:  1996-09       Impact factor: 2.736

Review 5.  Juvenile dermatomyositis presenting with rash alone.

Authors:  D M Eisenstein; A S Paller; L M Pachman
Journal:  Pediatrics       Date:  1997-09       Impact factor: 7.124

6.  Juvenile amyopathic dermatomyositis: results of a case finding descriptive survey.

Authors:  S Plamondon; P B Dent
Journal:  J Rheumatol       Date:  2000-08       Impact factor: 4.666

7.  Amyopathic dermatomyositis associated with transitional cell carcinoma of the bladder.

Authors:  B W Russ; J C English; D H King; D P Halbach
Journal:  Cutis       Date:  1999-02

Review 8.  Familial dermatomyositis.

Authors:  S Plamondon; P B Dent; A M Reed
Journal:  J Rheumatol       Date:  1999-12       Impact factor: 4.666

9.  Epidermal nuclear CIq deposits in a patient with amyopathic dermatomyositis.

Authors:  S Shirai; K Tomita; F Furukawa
Journal:  Eur J Dermatol       Date:  1999-03       Impact factor: 3.328

10.  Cutaneous changes of dermatomyositis in patients with normal muscle enzymes: dermatomyositis sine myositis?

Authors:  M R Stonecipher; J L Jorizzo; W L White; F O Walker; E Prichard
Journal:  J Am Acad Dermatol       Date:  1993-06       Impact factor: 11.527

View more
  1 in total

1.  Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis.

Authors:  Yuzo Suzuki; Hiroshi Hayakawa; Seiichi Miwa; Masahiro Shirai; Masato Fujii; Hitoshi Gemma; Takafumi Suda; Kingo Chida
Journal:  Lung       Date:  2009-04-22       Impact factor: 2.584

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.